Skip to main content
Figure 2 | BMC Infectious Diseases

Figure 2

From: Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis’

Figure 2

Mycobacterial-antigen stimulated IFN-g responses in TB patients according to disease severity and circulating 25-hydroxyvitamin D levels. Diluted whole blood cells were stimulated with ESAT6 and M. tuberculosis sonicate (MTBs) and IFN-g measured in cell supernatants after 6 days of culture. The graphs depict IFN-g responses in patients classified into severity according to their TB scores (a-b); Severity Class I (TB score 0 to 5), Class II (TB score 6 – 7) and Class III (TB score ≥ 8) in response to stimulation with (a) ESAT6 and (b) MTBs, or according to their vitamin D levels (c-d); Optimal (>30 nmol/ml), Insufficient (20–30 nmol/ml) or Deficient (< 20 nmol/ml) in response to stimulation with (c) ESAT6 and (d) MTBs. The box and whiskers plots depict cytokine responses in the 10th to 90th percentiles with the horizontal bar indicating the median levels of each group.

Back to article page